leisure time -WSS

leisure time

author：knowledge 2025-09-30 02:09:11 - browse：2956

A sign of The Cigna Group in front of trees with orange and green leaves — insurance overage from STAT — Joe Buglewicz/Bloomberg

Cigna and Humana are in discussions to merge, a potential move that would create a health insurance and prescription drug benefits titan with approximately $300 billion of annual revenue.

A proposed transaction would almost certainly prompt a close review from antitrust enforcers at the Department of Justice and the Federal Trade Commission. A merged Cigna-Humana would further consolidate the market for pharmacy benefit managers. PBMs are companies that serve as the controversial middlemen of drug pricing negotiations, and of the four largest, two are owned by Cigna and Humana.

The Wall Street Journal first reported the talks between Cigna and Humana on Wednesday, citing sources close to the situation. Wendell Potter, a health insurance whistleblower who used to work at Cigna, also wrote about merger discussions between Cigna and Humana on his blog Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings

WSS

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

As digital health tech proliferates, a new institute aims to cut through hype

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Pharma budget tightening trickles down to Doximity

Medicare has a new plan to address drug shortages

hotspot

leisure time

explore

Supreme Court strikes down use of affirmative action

Faced with fears of OxyContin misuse, sales reps touted its safety

Activists slam private health insurers over coverage restrictions

Large hospital system sues Multiplan for low

Anesthesiologist group: stop taking Ozempic before surgery

Pharma budget tightening trickles down to Doximity

Duchenne breakthrough therapy leaves behind pioneering families

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

The high cost of giving birth even with insurance

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

knowledge

Novo acquires Inversago for up to $1 billion

Genentech weighs delaying cancer therapy after drug pricing law

As digital health tech proliferates, a new institute aims to cut through hype

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

CDC overhauls leadership of center that led response to Covid

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

focus

knowledge

focus

Wikipedia